巴西抗淀粉样蛋白疗法用于阿尔茨海默病治疗：巴西神经科学院认知神经病学与衰老科学部立场文件
Use of anti-amyloid therapies for Alzheimer's disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.
作者信息
Barbosa Breno José Alencar Pires, Resende Elisa de Paula França, Castilhos Raphael Machado, Borelli Wyllians Vendramini, Frota Norberto Anízio Ferreira, Balthazar Marcio Luiz Figueredo, Amato Augusto Celso Scarparo, Smid Jerusa, Barbosa Maira Tonidandel, Coutinho Artur Martins, de Souza Leonardo Cruz, Schilling Lucas Porcello, da Silva Mari Nilva Maia, Fernandes Gustavo Bruniera Peres, Bertolucci Paulo Henrique Ferreira, Nitrini Ricardo, Engelhardt Eliasz, Forlenza Orestes Vicente, Caramelli Paulo, Brucki Sonia Maria Dozzi, Studart Adalberto
机构信息
Academia Brasileira de Neurologia, Departamento Científico de Neurologia Cognitiva e do Envelhecimento, São Paulo SP, Brazil.
Universidade Federal de Pernambuco, Centro de Ciências Médicas, Área Acadêmica de Neuropsiquiatria, Recife PE, Brazil.
出版信息
Dement Neuropsychol. 2024 Nov 11;18:e2024C002. doi: 10.1590/1980-5764-DN-2024-C002. eCollection 2024.
Novel therapies for Alzheimer's disease, particularly anti-amyloid drugs like lecanemab and donanemab, have shown modest clinical benefits but also significant risks. The present paper highlights the challenges of access to diagnosis, cost-effectiveness, safety, and the need for more representation of diverse populations in clinical trials. Recommendations include careful patient selection, risk-benefit analysis, and the importance of proven amyloid pathology for treatment. Future work involves further research on anti-amyloid therapies in Brazil and the development of more effective treatments for Alzheimer's disease.
治疗阿尔茨海默病的新型疗法，尤其是像乐卡奈单抗和多奈单抗这样的抗淀粉样蛋白药物，已显示出一定的临床益处，但也存在重大风险。本文强调了在诊断可及性、成本效益、安全性方面面临的挑战，以及临床试验中需要更多样化人群的代表性。建议包括谨慎选择患者、进行风险效益分析，以及治疗中已证实的淀粉样蛋白病理学的重要性。未来的工作包括在巴西对抗淀粉样蛋白疗法进行进一步研究，以及开发更有效的阿尔茨海默病治疗方法。
Zotero 插件